Manan M. Nayak

Manan M. Nayak

Auto-generated profile, based on publicly available information

Manan M. Nayak

Department of Psychosocial Oncology and Palliative Care, Dana-Farber Cancer Institute, 450 Brookline Ave., Boston, MA 02115, United States of America; Phyllis F. Cantor Center, Research in Nursing and Patient Care Services, Dana-Farber Cancer Institute, 450 Brookline Ave., Boston, MA 02115, United States of America; Department of Medicine, Harvard School of Medicine, Boston, Massachusetts, United States of America

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

26 November 2022 in Journal of Cancer Survivorship
Verified
Journal Article
Open access
PDF file
MNManan M. Nayak
Manan M. Nayak
ARAnna Revette
Anna Revette
PCPeter R Chai
Peter R Chai
KLKristina Lansang
Kristina Lansang
TSTimothy Sannes
Timothy Sannes
IBIlana M. Braun
Ilana M. Braun
Background: Although the vast majority of medical cannabis laws in the USA includes cancer as a qualifying condition and medical cannabis-related stigma influences decision-making regarding the botanical, few studies have explored the phenomenon in oncology. Early findings indicated oncologic cannabis-related stigma to be quite widespread. Methods: Semi-structured interviews with 24 adults with cancer histories using medical cannabis were analyzed using the Health Stigma and Discrimination Framework. Results: Sixteen out of 24 participants discussed medical cannabis-related stigma in some depth. The phenomena emerged as more pervasive in medical than personal/professional domains and was internalized as well as experienced directly. It led some participants, but not others, to practice partial or complete secrecy. Discussion: Taken together, our findings suggest that, while medical cannabis-related stigma remains widespread and led some study participants to alter behavior, an early shift in ethos towards greater medical cannabis acceptance could be underway. If so, this transition may be occurring more rapidly in non-medical than in clinical settings. Conclusion: Cancer survivors may experience heightened medical cannabis-related stigma in the clinic as compared to their personal/professional lives. Healthcare providers who depend on patient transparency when gathering medical histories and devising care plans may wish to neutralize perceptions of medical cannabis-related stigma.

20 April 2017 in Psycho-Oncology
Verified
Journal Article
Closed access
PDF file
ABAmanda C. Blok
Amanda C. Blok
TBTraci M. Blonquist
Traci M. Blonquist
MNManan M. Nayak
Manan M. Nayak
DSDarryl Somayaji
Darryl Somayaji
SCScott Crouter
Scott Crouter
MCMary E. Cooley
Mary E. Cooley

29 May 2018 in BMC Medical Informatics and Decision Making
Verified
Journal Article
Open access
PDF file
MCMary E. Cooley
Mary E. Cooley
JAJanet L. Abrahm
Janet L. Abrahm
DBDonna Berry
Donna Berry
MRMichael S. Rabin
Michael S. Rabin
IBIlana M. Braun
Ilana M. Braun
DLDavid F. Lobach
David F. Lobach
It is essential that cancer patients understand anticipated symptoms, how to self-manage these symptoms, and when to call their clinicians. However, patients are often ill-prepared to manage symptoms at home. Clinical decision support (CDS) is a potentially innovative way to provide information to patients where and when they need it. The purpose of this project was to design and evaluate a simulated model of an algorithm-based CDS program for self-management of cancer symptoms. This study consisted of three phases; development of computable algorithms for self-management of cancer symptoms using a modified ADAPTE process, evaluation of a simulated model of the CDS program, and identification of design objectives and lessons learned from the evaluation of patient-centered CDS. In phase 1, algorithms for pain, constipation and nausea/vomiting were developed by an expert panel. In phase 2, we conducted usability testing of a simulated symptom assessment and management intervention for self-care (SAMI-Self-Care) CDS program involving focus groups, interviews and surveys with cancer patients, their caregivers and clinicians. The Acceptability E-scale measured acceptability of the program. In phase 3, we developed design objectives and identified barriers to uptake of patient-centered CDS based on the data gathered from stakeholders. In phase 1, algorithms were reviewed and approved through a consensus meeting and majority vote. In phase 2, 24 patients & caregivers and 13 clinicians participated in the formative evaluation. Iterative changes were made in a simulated SAMI-Self-Care CDS program. Acceptability scores were high among patients, caregivers and clinicians. In phase 3, we formulated CDS design objectives, which included: 1) ensure patient safety, 2) communicate clinical concepts effectively, 3) promote communication with clinicians, 4) support patient activation, and 5) facilitate navigation and use. We identified patient barriers and clinician concerns to using CDS for symptom self-management, which were consistent with the chronic care model, a theoretical framework used to enhance patient-clinician communication and patient self-management. Patient safety and tool navigation were critical features of CDS for patient self-management. Insights gleaned from this study may be used to inform the development of CDS resources for symptom self-management in patients with other chronic conditions.

28 May 2003 in Medical Principles and Practice
Verified
Journal Article
Closed access
RGR. Gupta
R. Gupta
MNM. Nayak
M. Nayak
MKM. Khoursheed
M. Khoursheed
SRS. Roy
S. Roy
ABA.I. Behbehani
A.I. Behbehani
Objectives: The aim of this study was to systematically assess the pain experienced by patients undergoing mammography for various clinical presentations. Subjects and Methods: Two hundred and twenty-five patients aged 25–85 years (45.43 ± 8.25 years) presenting for mammography were included in the study. Presenting symptoms and clinical diagnosis were provided by the referring physicians and demographic information was obtained from self-reported questionnaires. Mammography results were recorded by the radiologist. Two different but reliable and valid measures of pain – Visual Analog Scale (VAS) and Pain/Discomfort Rating Scale (DRS) – were used to assess pain during mammography and data were statistically analyzed to examine the possible predictors of pain. Results: Forty-nine percent of the patients reported pain during mammography when cut-off level of VAS score was 40; however, when the cut-off level was raised to 60 (considering the preexisting pain as presenting symptom in some patients) only 23% reported pain. With DRS, 7% reported pain, 27% discomfort and 66% neither pain nor discomfort. Biserial correlation between the VAS and DRS scores suggested strong positive agreement between the two measures of pain (r = 0.56, d.f. = 90, p < 0.01). Patients presenting with coexisting breast lumps and preexisting breast pain and those diagnosed with inflammatory conditions of the breast and fibrocystic changes experienced more pain during mammography. Conclusion: Preexisting breast pathologies and demographic factors such as age and educational level of the patient were important in reporting pain during mammography. This finding indicates that proper assessment of pain using standard measures and its association with breast pathologies and demographic factors is important for planning pain management in women undergoing mammography.

15 August 2022 in JCO Oncology Practice
Verified
Journal Article
Open access
IBIlana M. Braun
Ilana M. Braun
MNManan M. Nayak
Manan M. Nayak
JRJane E. Roberts
Jane E. Roberts
PCPeter R. Chai
Peter R. Chai
JTJames Tulsky
James Tulsky
WPWilliam Pirl
William Pirl
PURPOSE: A growing body of scientific research indicates that oncology teams tend to offer individuals with cancer little clinical advice regarding medicinal cannabis (MC) and that individuals with cancer instead turn to cannabis dispensaries for MC guidance. Our objective was to investigate dispensary personnel's backgrounds and trainings in MC advising. METHODS: The study design was semistructured interviews across 13 states with cannabis dispensary personnel in managerial or client-facing positions. Of 38 recruited, 26 (68%) completed interview. The primary outcome was training in MC advising. Researchers targeted thematic saturation and adhered to Consolidated Criteria for Reporting Qualitative Research. RESULTS: Of 26 participants, 54% were female, with an average age of 40 (range: 22-64) years. Half worked in client-facing roles; half worked in managerial ones. Study participants endorsed passionate commitment to their profession, often motivated by personal experience with MC therapeutics. Cannabis dispensaries often privileged sales skills over cannabis therapeutics knowledge when hiring, resulting in uneven baseline levels of cannabis therapeutics expertise among staff. Most participants reported workplace cannabis therapeutics training to be unstandardized and weak. They described dispensary personnel as resourceful in pursuing cannabis knowledge, self-financing learning in off-hours, sampling dispensary products, and exchanging knowledge. Nearly half the participants called for quality, standardized cannabis therapeutics training for dispensary personnel. CONCLUSION: The many oncology teams who defer to dispensary personnel regarding MC advising rely on a workforce who views themselves as unevenly trained. Further research should include a national survey of cannabis dispensary personnel to learn whether these findings hold true in a larger sample. If so, the oncology community must determine the best approach to clinically advising individuals with cancer about MC.